Government Code § 549.0105
The commission must tell pharmaceutical manufacturers about any clinical edits or protocols that may apply before or during supplemental rebate negotiations, and clinical edits cannot be imposed on a preferred drug during the contract period unless that disclosure is made.
- Jurisdiction
- United States — Texas
- Instrument
- Code
- Version
- Undated source snapshot
- Language
- en
- Official source
- View official record ↗
drug rebates pharmaceutical negotiations preferred drug list
Statute overview
About this statute
This page preserves the statute’s identified version, provision structure, official source link, and stored legal text for reading and research.
Ask AI about this statute
Government Code § 549.0105
Sign in to ask AI about this statute
Sign in to start authenticated, citation-grounded statute research.
Sign inLexChat organizes source-backed legal information for research. Verify amendments, commencement, and current legal force with the official publisher before relying on it.